The University of New Mexico Comprehensive Cancer Center (UNMCCC) and the Department of Internal Medicine, Division of Hematology/Oncology at the UNM School of Medicine invite physicians and physician-scientists who are medical oncologists with significant experience and expertise in experimental therapeutics, preclinical and IND enabling trial design for novel targeted cancer therapies, and the design and conduct of early phase human cancer clinical trials. The successful applicant will have the training, significant experience, and expertise in developing and conducting early-phase clinical trials (first-in-human, phase zero, and phase I) and will be expected to lead and grow the UNMCCC Early Phase Clinical Trial Program in solid tumors, with an emphasis on rapid and informative translation from the bench-to-bedside-and-back with new therapeutics discovered and developed in concert with the UNMCCC Research Programs. This UNMCCC position includes opportunities to collaboratively support growth in drug discovery, drug repurposing, ligand-directed targeting, personalized genomics, and biotechnology/nanotechnology which is a top UNMCCC priority. Superb collaborative opportunities exist with the UNMCCC Consortium partners in high-end technology and advanced material or computer sciences (at Sandia and Los Alamos National Laboratories) and GLP toxicology (Lovelace Respiratory Research Institute). This is an Open Rank, Open Track position, but experienced mid-career and senior-level applicants are strongly preferred. Faculty rank and appointment will be commensurate with accomplishments. Excellent salaries, endowed positions, and start-up packages are available.
Minimum qualifications include:
M.D. or MD/Ph.D. degree or equivalent with board certification in Internal Medicine;
Board certification in Medical Oncology and/or Hematology;
Significant experience and/or medical oncology fellowship or post-fellowship comprehensive training in the design and conduct of early-phase clinical trials and investigator-initiated clinical trials;
Understanding of and/or experience in the NIH/NCI clinical trials systems including CTEP-supported early phase trials, biotechnology start-up environment, FDA drug requirements, and navigating pharmaceutical industry trials and sponsorship;
Must be eligible to work in the U.S.
Preferred qualifications include:
Experience in clinical and translational research
Experience in clinical trial regulatory requirements and affairs;
A demonstrated commitment to diversity, equity, and inclusion especially in the design of and enrollment to clinical trials, and other stakeholder success, as well as working with broadly diverse communities.
The University of New Mexico Comprehensive Cancer Center is the Official Cancer Center of New Mexico and the only National Cancer Institute-designated Cancer Center in a 500-mile radius. Its more than 120 board-certified oncology specialty physicians include cancer surgeons in every specialty (abdominal, thoracic, bone and soft tissue, neurosurgery, genitourinary, gynecology, and head and neck cancers), adult and pediatric hematologists/medical oncologists, gynecologic oncologists, and radiation oncologists as well as plastic and reconstruction surgeons. They, along with more than 600 other cancer healthcare professionals (nurses, nurse navigators, pharmacists, nutritionists, navigators, psychologists, and social workers), provide treatment to 65% of New Mexico’s cancer patients from all across the state and partner with community health systems statewide to provide cancer care closer to home. They treated approximately 14,000 patients in about 100,000 ambulatory clinic visits in addition to in-patient hospitalizations at UNM Hospital. A total of nearly 400 patients participated in cancer clinical trials testing new cancer treatments that include tests of novel cancer prevention strategies and cancer genome sequencing. The more than 100 cancer research scientists affiliated with the UNMCCC were awarded $35.7 million in federal and private grants and contracts for cancer research projects. Since 2015, they have published nearly 1000 manuscripts, and promoting economic development, they filed 136 new patents and launched 10 new biotechnology start-up companies. Finally, the physicians, scientists, and staff have provided education and training experiences to more than 500 high school, undergraduate, graduate, and postdoctoral fellowship students in cancer research and cancer healthcare delivery. UNM serves the population of New Mexico, a minority-majority state composed of nearly 50% Hispanic and 10 % American Indian. Only 62% of the state's population lives in urban areas and 7% live in frontier and sub-frontier regions. UNM is deeply committed to health equity and diversity, equity, and inclusion in all aspects of training, education, workforce, scientific discovery, and clinical care. Learn more at http://cancer.unm.edu/